Oncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Up 53.7% in April

Oncolytics Biotech Inc. (NASDAQ:ONCYGet Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 233,400 shares, a growth of 53.7% from the March 31st total of 151,900 shares. Based on an average daily volume of 259,700 shares, the days-to-cover ratio is currently 0.9 days.

Shares of Oncolytics Biotech stock opened at $1.32 on Friday. Oncolytics Biotech has a 52 week low of $1.25 and a 52 week high of $3.21. The business’s fifty day simple moving average is $1.54 and its 200-day simple moving average is $1.70. The firm has a market cap of $75.39 million, a PE ratio of -3.38 and a beta of 2.33.

Oncolytics Biotech (NASDAQ:ONCYGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. On average, research analysts expect that Oncolytics Biotech will post -0.47 earnings per share for the current year.

Several analysts recently commented on ONCY shares. Leede Jones Gab reiterated a “speculative buy” rating on shares of Oncolytics Biotech in a research report on Friday, March 4th. Canaccord Genuity Group lowered their price objective on Oncolytics Biotech from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, January 27th. Zacks Investment Research lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Wednesday, March 9th. Canaccord Genuity Group lowered their price objective on Oncolytics Biotech from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, January 27th. Finally, HC Wainwright reissued a “buy” rating on shares of Oncolytics Biotech in a research note on Monday, March 7th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Oncolytics Biotech has a consensus rating of “Buy” and an average price target of $7.25.

A number of institutional investors and hedge funds have recently bought and sold shares of ONCY. LPL Financial LLC lifted its stake in Oncolytics Biotech by 71.3% during the 3rd quarter. LPL Financial LLC now owns 20,489 shares of the company’s stock worth $43,000 after acquiring an additional 8,529 shares in the last quarter. Long Focus Capital Management LLC acquired a new position in Oncolytics Biotech during the 4th quarter worth about $56,000. UBS Group AG increased its holdings in Oncolytics Biotech by 29.5% during the 3rd quarter. UBS Group AG now owns 26,790 shares of the company’s stock worth $56,000 after purchasing an additional 6,101 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Oncolytics Biotech during the 3rd quarter worth about $70,000. Finally, Geode Capital Management LLC increased its holdings in Oncolytics Biotech by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 34,659 shares of the company’s stock worth $72,000 after purchasing an additional 10,114 shares during the period. 1.87% of the stock is currently owned by hedge funds and other institutional investors.

About Oncolytics Biotech (Get Rating)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.

See Also

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.